S ystemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by an undulating clinical course with inflammation in many different organ systems, including the skin, joints, heart, lungs, brain, blood, and kidneys. Patients with SLE are at increased risk for endothelial dysfunction, premature cardiovascular disease (CVD), and atherothrombosis. In particular, young female patients with SLE are 50 times more likely to develop myocardial infarction than matched healthy controls. 1 Platelet activity is a major factor in the development of CVD and has emerged as a potential contributor to SLE pathogenesis.
S ystemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by an undulating clinical course with inflammation in many different organ systems, including the skin, joints, heart, lungs, brain, blood, and kidneys. Patients with SLE are at increased risk for endothelial dysfunction, premature cardiovascular disease (CVD), and atherothrombosis. In particular, young female patients with SLE are 50 times more likely to develop myocardial infarction than matched healthy controls. 1 Platelet activity is a major factor in the development of CVD and has emerged as a potential contributor to SLE pathogenesis. 2 Several groups have demonstrated increased platelet activation in SLE measured by increased membrane expression of P-selectin, 3, 4 CD40 ligand, 3 annexin V, 4, 5 and complement deposition, 6, 7 as well as increased circulating platelet-leukocyte complexes. 3, 5, 8 Investigation of the platelet transcriptome in SLE also revealed upregulation of type I interferon-regulated genes. 5 Platelet-plasmacytoid dendritic cell complexes isolated from patients with SLE promoted interferon-α production in immune complex-stimulated plasmacytoid dendritic cells through the CD154-CD40 ligand pathway. 3 Furthermore, SLE platelets upregulated CD40 gene expression and concomitant release of soluble CD40 from mesangial cells, resulting in increased proliferation and production of transforming growth factor-β1 by these cells. 9 Depletion of platelets or administration of the P2Y12 receptor antagonist (clopidogrel) decreased serum concentrations of double-stranded DNA antibodies and proteinuria and improved kidney histological scores and overall survival in a murine lupus mouse model.
Endothelial dysfunction is an early identifiable event in the pathogenesis of atherosclerotic CVD 10 and has been reported in patients with SLE.
11 -13 Platelet activation and interaction with the endothelium may represent an important causal pathway contributing to accelerated CVD in patients with SLE. Accordingly, this study was initiated to evaluate platelet activity and consequent effects on endothelial cell function in SLE and healthy subjects.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Patient Population
Baseline demographics and clinical American College of Rheumatology criteria are presented in Table 1 . Mean age was 40 years, 81% were female, and 63% were nonwhite. Nearly two-thirds of the population fulfilled the renal American College of Rheumatology classification criteria for SLE. Clinical characteristics and treatment of the patients with SLE at the time of blood draw is noted in the Appendix in the online-only Data Supplement. The mean SLE disease activity index was 5.09±3.94 (range, 0-22).
SLE Platelets Have Increased Functional Activity
Previous data from our laboratory and others demonstrate that a submaximal concentration of agonists can identify populations with a hyperreactive platelet phenotype. [14] [15] [16] [17] Using submaximal concentrations of collagen or ADP, platelets isolated from patients with SLE demonstrated significantly greater aggregation compared with platelets isolated from matched controls ( Figure 1A and 1B). Although not statistically significant, there was a trend toward higher arachidonic acid-induced and spontaneous aggregation of platelets isolated from patients with SLE ( Figure 1C and 1D). To explore the functional consequences of SLE platelet activation, leukocyte-platelet aggregation was measured. There was a significant increase in leukocyte-platelet aggregates (P<0.0001) and monocyte-platelet aggregates (P<0.0001) in patients with SLE versus matched healthy controls (Figure 1E through 1H; Figure I in the online-only Data Supplement).
Because elevated levels of P-selectin and RANTES (regulated on activation, normal T-cell expressed and secreted) have been reported in SLE and are secreted by activated platelets, 4, 18, 19 these soluble proteins were measured in the blood of patients with SLE as an indirect measure of platelet activation. A positive correlation was observed between SLE disease activity as measured by the SELENA (Safety of Estrogen in Lupus National Assessment) SLE (E-selectin) disease activity index and soluble P-selectin (r=0.30; P=0.03; Figure IIA in the online-only Data Supplement) and RANTES levels (r=0.35; P=0.09; Figure IIB in the online-only Data Supplement). Both soluble P-selectin and RANTES were significantly higher in patients with SLE with proteinuria at the time of the blood draw compared with those without proteinuria (37.0±18.6 versus 20.6±13.7, 45.2±13.7 versus 29.9±7.6, respectively, P<0.05 for each comparison; Figure  IIC and IID in the online-only Data Supplement).
Identification of Genes Differentially Expressed in HUVECs Cocultured With SLE Platelets
To assess the relevance of platelet hyperreactivity, the platelet-endothelial cell axis was investigated. Thrombin-activated platelets (with a ratio of 100:1; platelet:endothelial cells) have significantly increased human umbilical vein endothelial cell (HUVEC) intercellular adhesion molecule 1 (ICAM-1) mRNA expression and interleukin-8 (IL-8) protein and mRNA expression when compared with resting platelets (Figure 2A and 2B; Figure III in the online-only Data Supplement). This effect was not because of thrombin because treatment of HUVECs with thrombin alone did not stimulate IL-8 or ICAM-1 mRNA expression (Figure 2A and 2B). Because SLE platelets were demonstrated to be hyperreactive (Figure 1 ), we hypothesized that SLE platelets would influence the phenotype of endothelial cells. Next, we selected platelets from 3 patients with SLE to explore associations of transcripts (microarray approach) of endothelial cells after coculture of platelets from these patients with SLE and HUVECs. The heatmap in Figure 3 illustrates distinct patterns of gene expression in HUVECs treated with platelets from subjects with SLE. IL-8 (mean fold change=41.5) and ICAM-1 (mean fold change=10.3) were among the most upregulated genes ( Figure IV in the online-only Data Supplement). These results were validated by testing for the induction of specific gene expression in HUVECs cocultured with SLE platelets. Transcripts for IL-8 (P<0.0001) and ICAM-1 (P<0.0001) were significantly increased in HUVECs cocultured with SLE platelets compared with no platelets ( Figure 4A and 4B). In addition, activation of HUVECs by SLE platelets was significantly greater for IL-8 (P=0.007) and ICAM-1 (P=0.02) than matched control platelets ( Figure 4A and 4B). A wide range of transcripts provided further evidence of endothelial cell activation, including the upregulation of 864 genes that were assigned by DAVID (Database for Annotation, Visualization and Integrated Discovery) to NOD (nucleotide-binding oligomerization domain)-like receptor signaling pathway, inflammatory and immune responses, leukocyte migration, and cytokine-cytokine receptor interaction. Gene ontology analysis for the most upregulated pathways is summarized in Table 2 . There were 552 downregulated genes in endothelial cells treated with SLE platelets. These transcripts serve to limit proinflammatory function of nuclear factor kappa beta (NFκB) and endothelial cell activation in response to inflammatory stimuli. 20 In particular, the expression of Kruppel-like factor 2 (KLF2), a zinc finger transcription factor that is a negative regulator of NFκB, was significantly decreased after HUVEC coincubation with SLE platelets (P=0.01; Figure V in the online-only Data Supplement).
SLE Sera Activates Platelets
To further elucidate the molecular mechanisms by which platelets in SLE become activated, SLE sera were evaluated for their capacity to activate washed platelets from healthy donors. Compared with control sera, SLE sera significantly activated platelets from healthy controls (P=0.006; Figure 5A ). SLE sera isolated from subjects with an SLE disease activity index ≥4 increased P-selectin expression on the surface of the control platelets to a greater extent than SLE sera from subjects with an SLE disease activity index <4 (P<0.0205; Figure 5B ). There was no significant association between platelet activation and the antiphospholipid antibody status of these patients, suggesting that other platelet-activating factors in the sera of lupus patients are likely involved (Figure VI in the online-only Data Supplement). To test the functional relevance of platelet activation induced by SLE sera, we assessed whether SLE sera could influence the adhesion of platelets to HUVECs. Fluorescence imaging showed that platelets activated by SLE sera were more adherent to HUVECs than platelets activated by control sera (P=0.001; Figure 5C and 5D). Furthermore, we observed a significant increase in HUVEC mRNA expression of IL-8, ICAM-1, and NFκB after coculturing with SLE sera-activated washed platelets ( Figure 5E ). IL-8, ICAM-1, or NFκB mRNA expression was not induced in HUVECs incubated with SLE sera alone ( Figure 5E ), suggesting a direct platelet-mediated activation of endothelial cells.
Platelets Activate Endothelial Cells in an IL-1-Dependent Manner
Because platelets exhibit membrane-associated interleukin-1 (IL-1) activity 21 and promote endothelial cell adhesion, 22, 23 the IL-1 pathway was evaluated as a potential mediator of SLE platelet-endothelial reactivity. Incubation of the human megakaryoblastic cell line, Meg-01, which exhibits similar properties to platelets and is frequently used as a model for human megakaryocytes with SLE sera, induced upregulation of IL-1β mRNA expression relative to cells incubated with sera from healthy controls ( Figure 6A ). On surface receptor activation, platelets have been shown to excise introns from IL-1β pre-mRNA, resulting in a mature message that is translated into protein. 22, 24 Consistently, we find IL-1β protein expression in platelets isolated from patients with SLE to be significantly increased when compared with healthy control subjects ( Figure 6B and 6C) . Platelet adhesion to HUVECs is mediated by IL-1β ( Figure 6D ), and treatment of platelets with SLE sera significantly increases platelet adhesion relative to control sera ( Figure 6D ; P=0.0034). Treatment of platelets with SLE sera in the presence of an IL-1β-neutralizing antibody significantly reduces adhesion to HUVECs, when compared with SLE sera-treated platelets in the presence of an IgG control (Figure 6E and 6F; P=0.013; Figure VII in the online-only Data Supplement). Inhibition of IL-1β in SLEtreated platelets reduced adhesion to the same degree as platelets treated with sera from healthy controls. Furthermore, SLE sera-activated platelets coincubated with HUVECs pretreated with an antibody to the IL-1β receptor were incapable of stimulating HUVEC gene expression of ICAM-1 ( Figure 6G and 6H). SLE sera alone, in the presence or absence of an antibody to the IL-1β receptor, did not modulate ICAM-1 expression ( Figure VIII in the online-only Data Supplement). Together, these results show that SLE-activated platelets likely contribute to endothelial dysfunction in patients with SLE via an IL-1β-dependent mechanism (Figure 7) . 
Discussion
Patients with SLE are at increased risk of accelerated CVD that remains unexplained by traditional risk factors. In this study, we demonstrated that SLE platelet activity is increased in the basal state and has increased IL-1β-dependent functional activity. Sera from SLE subjects significantly increased the activation of healthy donor-washed platelets, adhesion of platelets to HUVECs, and platelet-mediated endothelial cell expression of adhesive and inflammatory genes. An agnostic microarray of HUVECs cocultured with platelets from SLE subjects demonstrated an effect on endothelial cell activation pathways. Finally, we show that SLE-activated platelets induce endothelial cell activation via the IL-1β pathway. Together, these results are indicative that SLE-activated platelets contribute to impaired vascular health in patients with SLE and that this is mediated via an IL-1β-dependent mechanism.
Previous studies suggest that platelets from patients with SLE circulate in an activated state. [3] [4] [5] [6] [7] [8] Confirming and extending these results, we showed that SLE platelets are activated in the basal state, hyperreactive in response to submaximal doses agonist stimulation, and more likely to aggregate with leukocytes, neutrophils, and monocytes ( Figure 1) . Not all the agonists induced a significant difference between patients with SLE versus matched controls. This was most likely because of the limited number of samples in assessing light transmission aggregation. We also found that pretreatment of normal washed platelets with SLE sera increased P-selectin expression, a marker of platelet activity ( Figure 5 ). The underlying mechanism(s) of the increased platelet activity phenotype in SLE are unclear and remains to be elucidated. Both anticardiolipin antibody and the lupus anticoagulant are associated with complement deposition on SLE platelets. 25 Furthermore, ADP activation of platelets has been reported to be enhanced after incubation with SLE plasma positive for both anticardiolipin antibody and lupus anticoagulant, suggesting that platelet activation in SLE could be attributed, in part, to the combined effects of these antibodies. 26 However, in the present study, there was no association of antiphospholipid antibodies positivity (measured as either anticardiolipin antibody, anti-B2GPI, or lupus anticoagulant) with platelet activity or the ability of SLE sera-activated platelets to adhere to HUVECs or stimulate endothelial activation. These data suggest the involvement of other mediators in this process.
The growing literature regarding the proinflammatory capacity of platelets prompted us to investigate whether they could participate in the pathogenesis of CVD in SLE. Endothelial dysfunction is the earliest identifiable event in the process of atherosclerotic CVD, 10 and impaired endothelial function has been reported in patients with SLE and is associated with evidence of clinical coronary disease in that population. [11] [12] [13] It is also established that activated platelets act on endothelial cells by promoting adhesion and stimulating inflammatory processes. 22, 23, 27 We found that platelets isolated from patients with SLE induce inflammatory gene expression in endothelial cells (Figures 3 and  4) . In addition, pretreatment of normal washed platelets with SLE sera (versus control sera) promotes platelet-endothelial cell adhesion and upregulation of inflammatory and immune response signatures ( Figure 5 ). We cannot rule out the possibility that platelet-derived microparticles play a contributing role. 28 SLE and atherosclerosis are chronic inflammatory states, and both are associated with an increase in circulating proinflammatory cytokines, including IL-1β. 4, 29 Upregulation of IL-1β has been described in platelets 21, 30, 31 and megakaryocytes. 21, 32 In the current study, we found that megakaryocytes cultured with SLE sera increased the expression of IL-1β. Consistent with previous data, 23 endothelial cells had increased expression of inflammatory processes after coincubation of platelets with IL-1β. Blocking IL-1β-mediated adhesion with a neutralizing antibody was able to significantly decrease platelet adhesion to endothelial cells. In a study of rheumatoid arthritis, platelets amplify inflammation in synovial fibroblasts via IL-1. 28 Consistently, inhibition of the IL-1β receptor attenuated the inflammatory response of endothelial cells. Animal studies provide consistent support for Interleukin-1β (IL-1β) is upregulated in platelets from systemic lupus erythematosus (SLE) subjects and promotes endothelial inflammation. A, IL-1β mRNA expression in Meg-01 cells after incubation with 10% healthy control (n=7) or SLE sera (n=14). B, Platelets from patients with SLE (n=7) have increased IL-1β protein expression compared with platelets isolated from healthy controls (n=6), as determined by Western blotting. A representative blot of IL-1β protein expression from 2 patients with SLE and 2 healthy controls. C, Densitometry analysis of IL-1β expression performed in ImageJ. IL-1β expression expressed relative to GAPDH. D, Quantification of platelet adhesion to human umbilical vein endothelial cells (HUVECs) after platelet incubation with buffer, IL-1β (20 ng/mL), sera from control subjects (n=4), or sera from patients with SLE (n=8) for 2 hours at 37°C. E, Representative images of platelet adhesion to HUVECs after platelet incubation with healthy control (n=4) or SLE sera (n=8) in the presence of an IL-1β neutralizing antibody (10 ng/mL) or an IgG control antibody (10 ng/mL) for 2 hours at 37°C. Vehicle represents platelets incubated with buffer. Platelet adhesion to HUVECs is monitored by prelabeling of platelets with 3 μmol/L CellTracker dye (green), and HUVECs are stained with DAPI (4',6-diamidino-2-phenylindole). Magnification ×20. this pathway, including the demonstration of reduced lesions in atherosclerosis-prone mice deficient in either IL-1 or the type I IL-1 receptor. 33, 34 The Canakinumab Anti-inflammatory Thrombosis Outcomes Study is investigating whether IL-1β inhibition can lower cardiovascular events in patients with atherosclerosis. 35 Whether these properties of IL-1 inhibition could clinically influence platelet-mediated effects, endothelial dysfunction, and CVD in SLE remains to be examined.
Impaired endothelial function and endothelial cell activation is evident in patients with SLE with accelerated atherosclerosis. [36] [37] [38] This common pathogenic mechanism converges on transcription factors, such as NFκB, to regulate the expression of various chemokines, cytokines, and adhesion molecules. 39 Our study demonstrates, for the first time, endothelial cell activation by platelets isolated from patients with SLE. The array showed a significant upregulation of NFκB and its target genes (ICAM-1, VCAM-1, and SELE) in endothelial cells treated with SLE platelets. Similarly, endothelial cells treated with SLE sera-activated control platelets exhibited a significant increase in NFκB, IL-8, and ICAM-1 gene expression. Consistently, KLF2, a negative regulator of NFκB, was downregulated. Demonstration of increased ICAM-1 and IL-8 expression in endothelial cells treated with SLE platelets compared with healthy control platelets supports that endothelial activation is a response specific to platelets from patients with SLE. Importantly, SLE sera alone did not affect endothelial cell gene expression, suggesting that its effect is platelet mediated. A study of patients with sickle cell disease, a disease that also manifests with platelet activation 40, 41 and thrombotic complications, 42 demonstrated endothelial activation by sickle cell platelets. 43 In the current study, platelets isolated from patients with SLE increased HUVEC adhesion and stimulated gene expression of IL-8, ICAM-1, and other genes regulated by the NFκB pathway in HUVECs. We also observed that SLE sera-activated normal washed platelets exhibited increased adhesion to HUVECs and subsequent endothelial cell expression of IL-8, ICAM-1, and NFκB. Taken together, these data suggest that hyperreactive platelet adhesion and activation of endothelial cells may represent a common mechanism underlying the pathogenesis of various diseases with thrombotic complications via endothelial activation.
Platelet activity is a major mediator of atherothrombosis, and its inhibition can prevent incident cardiovascular events. 44 This study demonstrates a heightened platelet phenotype in SLE and consequent endothelial cell activation. Whether inhibition of platelet activity in SLE would have beneficial effects on atherothrombosis or endothelial function remains unclear. However, studies using antiplatelet therapy in a lupus mouse model provide encouraging results. One such study demonstrated improved measures of disease and overall survival with platelet depletion or administration of the P2Y12 receptor antagonist, clopidogrel. 3 In addition, several studies implicate the JAK/STAT (Janus kinase/signal transducer and activator of transcription) pathway in the pathogenesis of SLE. [45] [46] [47] STAT3 inhibition has been shown to delay the onset of lupus nephritis in lupus-prone mice. 48 Furthermore, the selective Jak2 inhibitor, tyrphostin AG490, significantly reduced proteinuria, improved renal function, and attenuated renal lesions in a murine lupus nephritis model. 49 In our array, we showed that the transcription factor IRF1 and its respective target gene HIVEP2, both targets of the JAK/STAT pathway, are upregulated in endothelial cells activated by SLE platelets. Recently, platelet activity has been shown to be regulated by the JAK/STAT3 signaling axis, independent of STAT3 transcription factor activity. 50, 51 STAT3 inhibition may be useful in not only attenuating platelet activation but also modulating the downstream effects on endothelial cell activation in the pathogenesis of SLE-accelerated atherosclerosis.
In conclusion, SLE-activated platelets induce endothelial cell activation via an IL-1β pathway. As illustrated in Figure 7 , our data indicate that platelets isolated from patients with SLE have increased activity in the basal state and are hyperreactive to submaximal agonist stimulation. Platelets from patients with SLE are hyperactive, affect endothelial cell activation, and thus may contribute to the development of CVD. The clinical consequences of these findings remain to be explored, but one could speculate that targeting platelet activity with IL-1β inhibition would not only inhibit this hyperreactive platelet phenotype in SLE but would attenuate crosstalk between platelets and endothelial cells and thereby improve vascular health.
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